Clinical data | |
---|---|
Trade names | Eumydrin |
Other names | Methylatropinium |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C18H26NO3 |
Molar mass | 304.410 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Methylatropine (trade name Eumydrin) is a belladonna derivative.
In 1902, the Bayer Company introduced methylatropine, a quaternary ammonium salt of atropine, as a mydriatic for dilation of the pupil during ophthalmic examination under the brand name of Eumydrin. Because of its highly polar nature it penetrated less readily into the central nervous system than did atropine; hence it was introduced for relieving pyloric spasm in infants.[1]
The blocking potency of methylatropine is approximately 10-20 times higher than that of atropine at neuromuscular and ganglionic synapses.[2]
See also
References
- ↑ "Methylatropine Bromide". Inxight: Drugs. National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, U.S. Department of Health and Human Services.
- ↑ Gyermek L (1998). "Semisynthetic Derivatives of Tropane Alkaloids and of other Tropane Esters". Pharmacology of Antimuscarinic Agents. Boca Raton: CRC Press. p. 162. ISBN 978-0-8493-8559-9.
This article incorporates public domain material from Methylatropine Bromide. National Institutes of Health.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.